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ABSTRACT 
Objective: The pericarp of fruits of Cucumis callous (Rottl.) Cogn. (Cucurbitaceae) is traditionally used for curing diabetes, epilepsy, and diarrhea. It 
has an active compound include Cucurbitacin-B (CuB), which acts as a potent inducer of CYP450 of rat enterocytes. This study was conducted with 
the aim of elaborating and reconciling our previous finding on the glucose-lowering effect of Cucumis callosus (Rottl.) Cogn. fruits. 
Methods: In vivo hypoglycemic potential for methanolic pericarp extracts from C callosus (MPCC, 350 mg/kg b.w. p. o), methanolic seed extract of C 
callosus (MSCC, 250 mg/kg b.w. p. o) and CuB (80 µg/kg b.w. p. o) were studied in streptozotocin (STZ, 55 mg/kg b.w. i. p) induced diabetic rats. 
Metformin (25 mg/kg b.w. p. o) served as reference drug. Ex vivo model of intestinal tissue preparation of Swiss albino rats named Single Pass 
Intestinal Perfusion (SPIP) technique was performed for ex vivo hypoglycemic study. The glucose levels in the serosal fluid were determined by 
commercially available glucose oxidase kit and compared with the standard drug metformin (0.1 mg/kg).  
Results: In vivo results showed that administration of MPCC (350 mg/kg b.w. p. o) and Cucurbitacin-B (80 µg/kg b.w. p. o) produced the 
hypoglycemic effect. The MPCC (1.4 mg/kg) and CuB (0.4 µg/kg) produced hypoglycemic effect in ex vivo technique. These effects are due to 
induction of 0.53 mµmoles of CYP450 proteins with maximum absorption at 454 mµ in rat enterocytes.  
Conclusion: The present investigation gave evidence that bitter pericarp of C callosus fruit has a hypoglycemic effect due to the presence of 
Cucurbitacin B as phytoconstituent but seeds did not have such effects. 
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Hyperglycemia is the net result of glucose influx exceeding glucose 
outflow of the plasma compartment. Abnormal islet cell function is a 
key and requisite feature of hyperglycemia [1, 2]. The chronic 
hyperglycemia is associated with long-term damage, dysfunction 
and eventually the failure of organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels [3, 4]. The management of diabetes 
is a global problem until now and successful treatment is not yet 
discovered [5]. Treatment of oral hypoglycemic agents is associated 
with side effects related to pharmacokinetic properties, secondary 
failure rates, hypoglycemia, gastrointestinal disturbances, skin 
reactions, haematological disorders, and rise in hepatic enzyme level 
[6, 7]. Hypoglycemic herbs are widely used as a non-prescription 
treatment for diabetes. However, few herbal medicines have been 
well characterized and demonstrated the efficacy in systematic 
clinical trials as those of Western drugs [8].  
Herbal medicines (HMs) with a bitter flavor and cold property may 
have multiple antidiabetic mechanisms and have exact antidiabetic 
effect with small toxic/side effect compared with western drugs. 
HMs with same property can be a complementary and alternative 
treatment for DM [9, 10]. Cucumis callosus (Rottl.) Cong. (Family-
Cucurbitaceae) is a highly branched perennial herb, mostly 
distributed over northern and eastern part of India [11-13]. Fruits 
are commonly known as Bitter Cucumber in English, Kachri in Hindi 
and Karkati in Sanskrit. The pericarp of fruit is very bitter taste than 
endocarp. Seeds are tasteless. The fruit is useful in jaundice, cerebral 
congestion, colic, constipation, dropsy, fever, worms, and sciatica 
[14, 15]. Root is given in cases of abdominal enlargement, cough, 
asthma, inflammation of the breast, ulcers, urinary diseases and 
rheumatism (16). The leaf extract is topically used in Wound healing 
[17]. The methanol extract from fruits has been reported on its 
antidiabetic, antioxidant and antihyperlipidemic activity [18]. The 
oil from seeds is used for poisonous bits, bowel. Complaints, 
epilepsy and also for blackening the hair [19]. In India (Eastern 
Odisha and West Bengal), ripe fruits are eaten raw and used in 
curries, green fruit used as a vegetable, dried pericarp of fruits used 
to control blood sugar level [20]. 
The objective of the investigation was to isolate lead molecules from 
methanolic pericarp extract of C callosus (MPCC) and to explore 
there in vivo and ex vivo effects on plasma glucose. 
MATERIALS AND METHODS 
Ethics statement 
All the experiments were conducted in compliance with the 
guidelines of Ethics Committee of the International Association for 
the Study of Pain and with the approval of the Institutional Animal 
Ethical Committee (IAEC) of our University (KLPIAEC10/07/1702). 
Drugs and chemicals  
STZ, metformin were purchased from Himedia, Mumbai, India. The 
CuB was dissolved in DMSO to make 200 µM stock solution and kept 
at −20  °C. The stock solution was freshly diluted to the desired 
concentration just before use. All other reagents used were of 
analytical grade obtained from Merck specialties Private Limited, 
Mumbai, India. 
Plant material and extract preparation 
The C. callosus fruits (15 kg) were collected in the month of August 
2017 from village area of Kendrapara and Balasore district, Odisha 
(India). The plant was authenticated by M. S. Mondal, Botanical 
Survey of India, Kolkata, India, and a voucher specimen (CNH/1-
1(196)/2007/Tech-II/160) has been preserved in the Pharmacology 
Research Laboratory, Jadavpur University, Kolkata for future 
reference. All fruits were shade dried with separation of seeds and 
pericarp. The dried seed powder (200 g) and pericarp powder (800 
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g) were defatted with petroleum ether at 40 °C in a Soxhlet 
extraction apparatus and then extracted similarly with methanol. 
Methanol solvent was completely removed under reduced pressure 
to obtain a dry mass. Yields of extracts were found to be 1.8 % w/w 
and 7.6 % w/w, respectively. Both extracts were stored in vacuum 
desiccators for further use. The preliminary phytochemical 
screening of both products showed the presence of mainly 
flavonoids, saponin, and triterpenoids [21]. 
Thin layer chromatographic analysis (TLC) of the extract 
Commercial aluminum sheets silica gel 60F254 of 0.2 mm thickness 
(Merck, Art. 5554) plates of size 4 cm x 10 cm were used. The plant 
extracts were diluted with distilled water and applied onto the TLC 
plates by using fine glass capillaries to fine 1 cm bands. Plates were 
let to dry completely and developed in the saturated 
chromatographic chamber with various solvent systems to a 
distance of 8.5 cm at room temperature. All separated bands of 
compounds were analyzed by viewing under visible and UV254 lights, 
spraying with Vanillin/H2SO4, FeCl3,  and DPPH spraying reagents. 
The Rf value of each separated band was calculated.  
Column chromatographic, UV and FTIR analysis of the extract 
On the foundation of phytochemical screening and TLC study, 
isolation was done by column chromatography through isocratic 
elution technique with the help of solvent system Chloroform and 
ethyl acetate (9:1). Fractions were collected in small conical flasks 
and the rate of flow of mobile phase was restricted to 40 drops per 
minute. The isolated compounds were further characterized by UV 
and FTIR studies [22, 23]. FTIR analysis of the extract was carried 
out by αE BRUKER FTIR model. 
Acute toxicity study 
MPCC, MSCC, and CuB were administered orally to male Swiss albino 
mice to find out the LD50 
The perfusion buffer composition was as follows: CaCl
dose [24]. 
In vivo hypoglycemic study 
Induction of Experimental diabetes  
The rats were rendered diabetic by a single intraperitoneal dose of 
55 mg/kg b.w. STZ freshly dissolved in ice-cold 0.1 M citrate buffer 
(pH 4.5). After 72 h, fasting blood glucose (FBG) levels were 
measured and only those animals showing blood glucose level ≥ 225 
mg/dl were considered for the present investigation. The day on 
which hyperglycemia had been confirmed was designated as day 0. 
Determination of fasting blood glucose (FBG) level in STZ 
induced diabetic rats 
Thirty-six male Wistar albino rats (180–200 g) were divided into six 
groups (n = 6). The first group served as the normal non-diabetic 
control (saline control). Group II served as the diabetic control (STZ 
control). Groups III, IV, V and VI received MPCC (350 mg/kg b.w. p. 
o), MSCC (250 mg/kg b.w. p. o), CuB (80 µg/kg b.w. p. o) and 
Metformin (25 mg/kg b.w. p. o) respectively for 15 consecutive days. 
Blood glucose levels were measured on every 5th day during 15 d by 
using a digital balance and one-touch glucometer (Accu-Chek®). 
Ex vivo hypoglycemic study 
Preparation of perfusion solutions 
2 × 2H2O, 0.98 
mmol, KCl 2.58 mmol, Na2HPO4 0.66 mmol, NaH2PO4 5.1 mmol, 
NaCl 84 mmol, d-glucose 3.0 mmol with pH 6.8 (with NaOH) phenol 
red (50 mg L-1
25
) was added to the solution as a non-absorbable 
marker. The pH was adjusted to 7.4 [ ]. Preliminary experiments 
showed that there was no adsorption of the compounds to the 
catheters and the tubing. Test drug concentrations used in the 
perfusion studies were selected by dividing the therapeutic dose of 
the drug (350 mg/kg) by the accepted gastric volume (250 ml), so as 
to represent maximal concentration in the intestinal segment [26]. 
SPIP technique for evaluation of intestinal glucose uptake  
Single Pass Intestinal Perfusion (SPIP) studies were performed in 
Swiss albino rats after intraperitoneal injection of 25 mg/kg of 
thiopental sodium [27]. Animal care and handling throughout the 
experimental procedure were performed in accordance with the 
CPCSEA, India guidelines. After the onset of deep anaesthesia, the 
abdomen was opened by a midline longitudinal incision, and 
approximately 15 cm length of intestine immediately after 
stomach was selected, rinsed with frogs' ringer solution and 
cannulated on both sides. Care was taken in handling the small 
intestine to minimize the blood loss. Thirty male Wistar albino rats 
(180–200 g) were divided into five groups (n = 6). Rats were 
fasted for 24 h prior to the start of the experiment. The group I 
served as the normal saline control group. Group II, III and IV 
received MPCC 1.4 mg/kg b.w., MSCC 1 mg/kg b.w., and CuB 0.4 
µg/kg b.w. respectively for 1 hour. Group V received the reference 
drug metformin 0.1 mg/kg b. w for 1 hour. The glucose 
concentration of serosal fluid was calculated in all groups using 
the parallel-tube model (fig. 1) [28]. For studying the effect of the 
test compound on glucose (substrate) uptake, glucose was added 
into mucosal compartment fluid just before the start of the 
experiment. At the end of the incubation period (1 h), the sacs 
were removed from the flask and these sacs were emptied and the 
serosal fluid from the sacs was used for the estimation of glucose. 
Similar estimations were also performed on samples of mucosal 
fluid in the flasks. Glucose concentrations were measured using a 
commercially available glucose oxidase kit (Lifechem TM-Glucose-
LR). The loss of glucose from the mucosal fluid assumed to 
represent the glucose taken up by the intestine, and the rise in 
glucose in a serosal fluid, the glucose released. The difference is 
attributable to the glucose retained in the tissue. Amount of 
glucose transported from the mucosal compartment was 
characterized as “uptake” while the serosal gain of the substances 
is treated as “release”. Uptake and release of glucose were 
expressed as PM/g tissue. Permeability for glucose in each group 




Fig. 1: Single-pass intestinal perfusion (SPIP) system 
preparation using parallel-tube model for ex vivo hypoglycemic 
study 
 
Kinetic study on ex vivo glucose uptake 
A kinetic study was conducted to understand the transport/ 
inhibition of glucose across intestinal membrane. In terms of 
enzyme kinetics, the amount of glucose transported/h was analog to 
the velocity of transfer, in other words, to the concentration 
difference of the glucose between compartments at the beginning 
and end of an experiment [29]. The Michaelis-Menten constant (Km), 
which is the affinity of the transferring enzyme (glucose 
transporter) for the substrate (glucose). The maximal velocity 
(Vmax), which is the rate of transfer reaction in the presence as well 
as in the absence of the plant extracts was determined from the 
differences of the uptake and release values using Michaelis-Menten 
and the Line weaver-Burk Plots in Microsoft Excel. Comparison of 
difference between the control and experimental groups were 
examined using one-way analysis of variance (ANOVA). In each 
series of experiments, the controls were run either with or without 
test compound and results were corrected accordingly [30]. 
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Determination of cytochrome P450 
Swiss albino rats (200-240 g) were given single daily intraperitoneal 
injections of 100 mg/kg of sodium phenobarbital in normal saline 
for 3 d. Control rats received an equal volume of normal saline. The 
animals were starved overnight and sacrificed on the 4th day (24 h 
after the last injection of phenobarbital). 25% of intestine 
homogenate in isotonic KCl-0.01M phosphate buffer was prepared 
and the microsomal fraction is isolated. Microsomes were washed 
by resuspending the pellet in ice-cold 1.15% KCl, recentrifuged at 
100,000 × g for 60 min. The washing procedure removes most of the 
hemoglobin. The microsomal fraction isolated from the intestine 
(wet weight) were suspended in 6.0 ml of 0.05M phosphate buffer, 
pH 7.6 (EDTA) and kept for protein concentration measurement. 
The protein concentration of this suspension is measured as 2.5 
mg/ml. All subsequent procedures are done at room temperature. 2 
ml of the suspension is placed into each of two matched cuvettes 
with either Teflon or glass stoppers. A baseline is determined using 
the recording spectrophotometer (ROLEX) by scanning from 400-
500 mµ. Carbon monoxide is bubbled gently into the sample cuvette 
for 20 sec. A few milligrams of solid sodium dithionite (Na2SO4) was 
added. Then cuvette is inverted and carbon monoxide bubbled again 
for an additional 20 sec. Immediately after CO2 bubbling, the cuvette 
is tightly capped. Reference cuvette is treated only with a few 
milligrams of sodium dithionate and mixed well.  
The spectrum is recorded from 400 mµ to 500 mµ. Cytochrome 
P450 quantity is calculated from the optical density difference and 
the molar extinction coefficient of 91 mmol-1 cm-1
RESULTS 
. The quantity is 
calculated per mg of protein as per the below formula [26]. 
Optical density difference × 1000
91 × Mg of protein
= mµmoles of Cytochrome P450 
Acute toxicity study 
The MPCC showed toxic effect or death at the dose of 3500 mg/kg, 
b.w., p. o. in mice whereas MSCC showed a lethal effect at 2500 
mg/kg b.w., p. o. The LD50
There were distinctive TLC profiles of the seed and pericarp 
extracts. One phenolic antioxidant and five terpenoid compounds 
were characteristic to the pericarp extract whereas two phenolic 
and one terpenoid antioxidant were characteristic to the seeds 
extract (fig. 2). The study able to give a guide in isolating the 
antidiabetic compound. Chromatogram sprayed with 
Vanillin/H
 value of CuB was 8 mg/kg b.w., p. o. 
TLC profile of MPCC and MSCC  
2SO4 and viewed under the UV254 light showed 
terpenoidal compounds as pink or blue bands. Chromatogram 
sprayed with FeCl3
 
 showed phenolic compounds as dark blue bands. 
 
Fig. 2: (a) Chromatogram viewed under UV254 light. (b) 
Chromatogram sprayed with Vanillin/H2SO4. (c) 
Chromatogram sprayed with FeCl3
 
Column chromatographic, UV and FTIR spectrophotometric 
profile of the extract 
 and DPPH spraying reagent 
Fraction numbers 13-17 were found to show a single spot on TLC 
with different types of solvent system. This compound was termed 
as compound-1. Further gradient elution gave another compound 
(compound-2) infraction numbers 26–36. They were further 
characterized by UV, IR studies.  
The UV spectra showed λmax of compound-2 is 226 nm and is a white 
crystalline solid with a melting point is 186-188 °C The compound-2 
was compared with the reported works on different species of 
Cucurbitaceae family and it was found to be Cucurbitacin-B because 
Cucurbitacin-B is also white crystalline solid having mixed melting 
point 186-188 °C, λmax 226 nm, and FTIR peaks at 3500, 2950 and 
1690 Cm-1(fig. 3,4) [31]. Similarly, compound-1 was compared with 
the reported works and found to be Ebenone leucopentaacetate 








UV Chromatogram, λ 222 and 327 nm max 226 nm 
Fig. 3: UV Spectrophotometric determination of Ebenone leucopentaacetate and cucurbitacin-B 
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Fig. 4: FTIR spectra of cucurbitacin-B 
 
Spectrophotometric determination of cytochrome P450 
Lamda max: 454 nm; Absorbance: 0.122 
Optical density difference (400-500 mµ): 0.122 
Mg of protein in a cuvette: 2.5 
The quantity of CYP450 is 0.122×1000
91×2.5
 = 0.53 mµmoles per mg of 
protein. It showed maximum absorption at 454 mµ. 
  
 
Fig. 5: UV Spectrophotometric determination of microsomal CYP 450 of rat enterocytes 
 
Table 1: Effect of MPCC, MSCC, and CuB on fasting blood glucose (FBG) level in STZ induced diabetic rats 
Group Dose Blood glucose level mg/dl 
0 d 5th 10 d th 15d th d 
I (Saline control) 5 ml/kg (oral) 75.00±2.88 75.50±4.65 74. 66±2.62 77. 60±2.80 
II (STZ) 55 mg/kg (b.w. i. p.) 287.45±22.80 298.32±36.47 302.44±52.68 314.08±86.17 
III (STZ+MPCC) 350 mg/kg (b.w. p. o) 280.20±43.16 218.48±52.39 87.52±14.65* 70.86±12.70* 
IV (STZ+MSCC) 250 mg/kg (b.w. p. o) 278.50±28.86* 258.65±21.82* 190.50±28.65 157.46±7.80 
V(STZ+CuB) 80 µg/kg (b.w. p. o) 266.83±17.62 118. 45±18.25 118.75±8.60* 110.36±8.84* 
V(STZ+Metformin) 25 mg/kg (b.w. p. o) 290.83±11.94 138.48±12.65 88.70±6.20* 78.65±8.14* 
 Values are expressed as mean±SEM from n = 6, * p<0.001 compared with STZ-control group. 
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Table 2: Effects of MPCC, MSCC, and cucurbitacin-B on the uptake of varying concentrations of glucose by gut sacs of rats 
Glucose 
Concentration (mM) 
Uptake (µ mol/g tissue 
wet wt/h) Control (n=6) 









5.5 60.86±3.42 38.23±1.54* 35. 28±1.54* 60.86±3.42 41.63±1.54* 
6.5 66.25±3.23* 40.66±1.54* 38. 20±1.27 66.25±3.23* 42.17±1.54* 
7.5 78.45±4.42* 45.48±1.54 45. 26±2.32* 78.45±4.42* 52.30±1.54 
8.5 98.00±2.13 62.18±1.54* 56. 30±1.37* 98.00±2.13 70.18±1.54* 
The gut sacs were incubated in Kerbs-henseleit buffer (pH = 7.4) at 37 °C. Values are expressed as mean±SD of six experiments. *P<0.0001. n = 
number of sacs used. 
 
Table 3: Effect of MPCC, MSCC, and cucurbitacin-B: kinetic parameters of the transport of D-glucose at different concentrations (5.5-8.5) 
across the rat gut sacs 
Experiments (n = 6) Vmax K(mM/h) m (mM) 
Control  0.0828 20.74 
Cucurbitacin-B (0.4 µg/kg)  0.072 21.68 
MPCC (1.4 mg/kg) 0.066 23.52 
MSCC(1 mg/kg) 0.081 20.85 
Metformin (0.1 mg/kg) 0.078 22.65 
Km and Vmax values were obtained from Line weaver-Burk Plot. Km:  Michaelis-Menton constant, which is the affinity of the transferring enzyme for 
the substrate. Vmax:  
 
Maximal velocity, which is the rate of transfer reaction, in the presence as well as in the absence of extract determined from the 
differences of uptake and release values using Michaelis-Menten and Lineweaver-Burk Plots in Microsoft Excel. 
DISCUSSION 
Our previous report demonstrated in vitro hypoglycemic and 
antimicrobial activity of Cucumis callosus (Rottl.) Cogn. Fruits and 
assumed that high content of phenolic compounds terpenoids and 
flavonoids in the extract may be a contributing factor towards 
hypoglycemic activity [33]. Our current research isolated a 
triterpenoid named Cucurbitacin-B from Methanolic Pericarp 
Extract of C callosus (MPCC) and evaluated it's in vivo and ex vivo 
hypoglycemic activity. Here it is established that the hypoglycemic 
action of Cucurbitacin-B is due to its potential induction of novel 
protein such as CYP450 in enterocytes of Swiss albino rats. Ex 
vivo SPIP technique using different animal species including rat, 
rabbit, pig, dog, and monkey has been reported in the literature to 
study the intestinal absorption of drugs. Among these animal 
models, SPIP in the rat is a well-established technique to study the 
intestinal passive absorption of drugs with good correlation 
between human and rat intestinal absorption [34].  
Cytochrome P450 (CYP450) enzymes belong to a superfamily of 
heme-thiolate containing proteins that can metabolize a wide 
variety of substrates [35]. The expression pattern of CYPs is very 
broad in terms of tissue selectivity. However, the liver is the main 
organ comprising the highest abundance and largest amount of 
individual CYPs. Substantial amounts of CYPs can also be found in 
the intestine, lung, kidney, brain, adrenal gland, gonads, heart, nasal 
and tracheal mucosa, and the skin, which may contain the highest 
expression of certain CYP isoforms [36]. The function of Cytochrome 
P450s is not only limited to xenobiotic metabolism but also have 
roles in endobiotic functions, mainly in sterol, fatty acid, eicosanoid 
and lipid-soluble vitamin (A and D) metabolism. In addition, there 
are several CYPs whose substrates are yet to be identified and which 
may be potential endobiotic metabolizing enzymes [37]. CYP 
enzymes catalyze a wide variety of reactions. A common feature is 
that CYPs can through the iron in their heme group react with 
molecular oxygen (O 2
Errico et al., 2011, found significant Peroxisome proliferator-
activated receptor-γ coactivator 1-α (PGC-1α) levels in the 
entire 
) using NADPH as a cofactor, resulting in the 
formation of an oxidized substrate and water as a by-product. The 
most common reactions that the CYPs catalyze include carbon 
hydroxylation, heteroatom oxygenation, heteroatom release 
(dealkylation), epoxidation and aromatic hydroxylation, but some 
more complex reactions also exist [38]. 
gastrointestinal tract. Notably, PGC-1α is localized in the 
differentiated enterocytes that belong to the apical compartment of 
the epithelium. PGC1α induction helps to maintain mitochondrial 
integrity, enhance intestinal barrier function, and decrease 
inflammation. Depletion of PGC-1α in the intestinal epithelium 
contributes to inflammatory changes through a failure of 
mitochondrial structure and function as well as a breakdown of the 
intestinal barrier, which leads to increased inflammation and 
bacterial translocation [39]. Xenobiotic and endobiotic metabolizing 
CYP450 enzymes regulated by PGC-1α and also, PGC-1α is induced 
by metformin [38]. Metformin, a biguanide oral antihyperglycaemic 
agent, is widely used in the management of patients with T2D, 
particularly in those overweight and obese as well as those with 
normal renal function. It lowers the blood glucose concentration 
without causing hypoglycemia [40]. An increase in anaerobic 
metabolism in the intestinal wall is also probably a clinically 
significant antihyperglycaemic mechanism of metformin [41, 42]. Low 
dose metformin improves hyperglycemia better than acarbose in type 
2 diabetics [43]. So the overexpression of CYP450 in the intestinal 
epithelium by MPCC and CuB is due to induction of PGC-1α in the 
apical compartment of the epithelium, which enhance intestinal 
barrier function and increase anaerobic metabolism of glucose.  
The small intestine is mostly dominated by CYP3A, in particular, 
CYP3A4 and CYP3A5 [44]. The reduced pigment form of P-450 
readily combines with carbon monoxide to form a complex having 
an absorption maximum at 450 mµ and a minimum of 405 mµ. Thus, 
its presence can be detected spectrophotometrically only as a 
difference-spectrum in its carbon monoxide derivative form [45]. 
Presence of CYP450 protein in rat enterocytes is observed from its 
maximum absorption at 454 mµ.  
Glucose uptake into the cells across the cell membrane is dependent 
on the concentration gradient between the extracellular medium (e. 
g. blood plasma, gastrointestinal contents) and the cell interior. 
However, because glucose is such an important metabolite, there 
exist a number of membrane transport pumps or facilitators in 
certain tissues [46, 47]. The Michaelis-Menten constant (Km) of the 
glucose uptake was calculated for all the experiments. Km is the 
affinity of the transferring enzyme for the substrate. In the present 
study, it is simulated that Km is the affinity of the CYP450 enzyme. 
The maximal velocity (Vmax) is regarded as the glucose uptake rate 
in the presence as well as in the absence of plant extract. The 
decreased Vmax and increased Km in the presence of extract indicated 
that the affinity of transmembranal efflux glucose transport was 
significantly increased and velocity of glucose transport decreased 
[26]. So it is confirmed that the Cucurbitacin-B of pericarp extract 
may exhibit hypoglycemic action by inducing CYP450 enzyme which 
is comparable to reference drug metformin. 
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The hypoglycemic action of C callosus fruit is due to the presence of 
Cucurbitacin B in the pericarp of fruit. The mechanism of 
hypoglycemic action of pericarp extract is due to induction of 
CYP450 enzyme in enterocytes of the gut. Further research to 
identify the specific activity of P450 isoenzymes could further 
develop and also complement this tool. This study also buttresses 
the claim that Cucurbitacin-B (80 µg/kg) could be used as effective 
therapy for the management of postprandial hyperglycemia with 
minimal side effects. 
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